Cargando…
Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is a hypercoagulable state accompanied by the presence of heterogeneous antiphospholipid antibodies (aPL), which nonspecifically affect hemostasis by the presence of lupus anticoagulans (LA), anticardiolipin antibodies (aCL), antibodies against β2-glycoprotein-I (anti...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409152/ https://www.ncbi.nlm.nih.gov/pubmed/36012233 http://dx.doi.org/10.3390/ijms23168973 |
_version_ | 1784774780650520576 |
---|---|
author | Bradáčová, Pavla Slavík, Luděk Skoumalová, Adéla Úlehlová, Jana Kriegová, Eva Manukyan, Gayane Friedecký, David Piskláková, Barbora Ullrychová, Jana Procházková, Jana Hluší, Antonín |
author_facet | Bradáčová, Pavla Slavík, Luděk Skoumalová, Adéla Úlehlová, Jana Kriegová, Eva Manukyan, Gayane Friedecký, David Piskláková, Barbora Ullrychová, Jana Procházková, Jana Hluší, Antonín |
author_sort | Bradáčová, Pavla |
collection | PubMed |
description | Antiphospholipid syndrome (APS) is a hypercoagulable state accompanied by the presence of heterogeneous antiphospholipid antibodies (aPL), which nonspecifically affect hemostasis by the presence of lupus anticoagulans (LA), anticardiolipin antibodies (aCL), antibodies against β2-glycoprotein-I (anti-β2GPI), but also non-criteria antibodies such as antibodies against β2-glycoprotein-I domain I (anti-DI), anti-phosphatidylserine/prothrombin (anti-PS/PT), anti-annexin V, and many others. The main target of the antibodies is the activated protein C (APC) system, the elimination of which can manifest itself as a thrombotic complication. The aim of this study was to determine the thrombogenicity of antibodies using a modified protein C-activated thrombin generation assay (TGA) on a group of 175 samples suspected of APS. TGA was measured with/without APC and the ratio of both measurements was evaluated (as for APC resistance), where a cut-off was calculated ≤4.5 (90th percentile) using 21 patients with heterozygous factor V Leiden mutation (FV Leiden heterozygous). Our study demonstrates the well-known fact that multiple positivity of different aPLs is a more severe risk for thrombosis than single positivity. Of the single antibody positivity, LA antibodies are the most serious (p value < 0.01), followed by aCL and their subgroup anti-DI (p value < 0.05). Non-criteria antibodies anti-annexin V and anti-PT/PS has a similar frequency occurrence of thrombogenicity as LA antibodies but without statistical significance or anti-β2GPI1 positivity. The modified TGA test can help us identify patients in all groups who are also at risk for recurrent thrombotic and pregnancy complications; thus, long-term prophylactic treatment is appropriate. For this reason, it is proving increasingly beneficial to include the determination antibodies in combination with modified TGA test. |
format | Online Article Text |
id | pubmed-9409152 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94091522022-08-26 Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome Bradáčová, Pavla Slavík, Luděk Skoumalová, Adéla Úlehlová, Jana Kriegová, Eva Manukyan, Gayane Friedecký, David Piskláková, Barbora Ullrychová, Jana Procházková, Jana Hluší, Antonín Int J Mol Sci Article Antiphospholipid syndrome (APS) is a hypercoagulable state accompanied by the presence of heterogeneous antiphospholipid antibodies (aPL), which nonspecifically affect hemostasis by the presence of lupus anticoagulans (LA), anticardiolipin antibodies (aCL), antibodies against β2-glycoprotein-I (anti-β2GPI), but also non-criteria antibodies such as antibodies against β2-glycoprotein-I domain I (anti-DI), anti-phosphatidylserine/prothrombin (anti-PS/PT), anti-annexin V, and many others. The main target of the antibodies is the activated protein C (APC) system, the elimination of which can manifest itself as a thrombotic complication. The aim of this study was to determine the thrombogenicity of antibodies using a modified protein C-activated thrombin generation assay (TGA) on a group of 175 samples suspected of APS. TGA was measured with/without APC and the ratio of both measurements was evaluated (as for APC resistance), where a cut-off was calculated ≤4.5 (90th percentile) using 21 patients with heterozygous factor V Leiden mutation (FV Leiden heterozygous). Our study demonstrates the well-known fact that multiple positivity of different aPLs is a more severe risk for thrombosis than single positivity. Of the single antibody positivity, LA antibodies are the most serious (p value < 0.01), followed by aCL and their subgroup anti-DI (p value < 0.05). Non-criteria antibodies anti-annexin V and anti-PT/PS has a similar frequency occurrence of thrombogenicity as LA antibodies but without statistical significance or anti-β2GPI1 positivity. The modified TGA test can help us identify patients in all groups who are also at risk for recurrent thrombotic and pregnancy complications; thus, long-term prophylactic treatment is appropriate. For this reason, it is proving increasingly beneficial to include the determination antibodies in combination with modified TGA test. MDPI 2022-08-11 /pmc/articles/PMC9409152/ /pubmed/36012233 http://dx.doi.org/10.3390/ijms23168973 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bradáčová, Pavla Slavík, Luděk Skoumalová, Adéla Úlehlová, Jana Kriegová, Eva Manukyan, Gayane Friedecký, David Piskláková, Barbora Ullrychová, Jana Procházková, Jana Hluší, Antonín Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome |
title | Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome |
title_full | Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome |
title_fullStr | Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome |
title_full_unstemmed | Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome |
title_short | Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome |
title_sort | determination of thrombogenicity levels of various antiphospholipid antibodies by a modified thrombin generation assay in patients with suspected antiphospholipid syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409152/ https://www.ncbi.nlm.nih.gov/pubmed/36012233 http://dx.doi.org/10.3390/ijms23168973 |
work_keys_str_mv | AT bradacovapavla determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome AT slavikludek determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome AT skoumalovaadela determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome AT ulehlovajana determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome AT kriegovaeva determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome AT manukyangayane determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome AT friedeckydavid determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome AT pisklakovabarbora determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome AT ullrychovajana determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome AT prochazkovajana determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome AT hlusiantonin determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome |